It is certain that a key purpose of the trial is to beef up the specificity of EMU in confirming 'no stroke'. After all, all the trials so far have focused on patients with stroke or suspected stroke. Maybe a skewed data set that is now being corrected with a larger non-stroke patient sample - which makes sense for a 'stroke-no stroke' algorithm.
What I am not sure about is the ambivalence of the final sentence in your quote. It could arguably be either of the following interpretations:
This study hypothesises that an expanded non-stroke dataset can improve the diagnostic performance of the emu™ brain scanner in deciding stroke or no stroke' or it could mean 'This study hypothesises that an expanded non-stroke dataset can improve the diagnostic performance of the emu™ brain scanner in stroke detection and potentially other conditions' (my italics).
EMV Price at posting:
$1.86 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)